Literature DB >> 24078694

Characterization of distinct immunophenotypes across pediatric brain tumor types.

Andrea M Griesinger1, Diane K Birks, Andrew M Donson, Vladimir Amani, Lindsey M Hoffman, Allen Waziri, Michael Wang, Michael H Handler, Nicholas K Foreman.   

Abstract

Despite increasing evidence that antitumor immune control exists in the pediatric brain, these findings have yet to be exploited successfully in the clinic. A barrier to development of immunotherapeutic strategies in pediatric brain tumors is that the immunophenotype of these tumors' microenvironment has not been defined. To address this, the current study used multicolor FACS of disaggregated tumor to systematically characterize the frequency and phenotype of infiltrating immune cells in the most common pediatric brain tumor types. The initial study cohort consisted of 7 pilocytic astrocytoma (PA), 19 ependymoma (EPN), 5 glioblastoma (GBM), 6 medulloblastoma (MED), and 5 nontumor brain (NT) control samples obtained from epilepsy surgery. Immune cell types analyzed included both myeloid and T cell lineages and respective markers of activated or suppressed functional phenotypes. Immune parameters that distinguished each of the tumor types were identified. PA and EPN demonstrated significantly higher infiltrating myeloid and lymphoid cells compared with GBM, MED, or NT. Additionally, PA and EPN conveyed a comparatively activated/classically activated myeloid cell-skewed functional phenotype denoted in particular by HLA-DR and CD64 expression. In contrast, GBM and MED contained progressively fewer infiltrating leukocytes and more muted functional phenotypes similar to that of NT. These findings were recapitulated using whole tumor expression of corresponding immune marker genes in a large gene expression microarray cohort of pediatric brain tumors. The results of this cross-tumor comparative analysis demonstrate that different pediatric brain tumor types exhibit distinct immunophenotypes, implying that specific immunotherapeutic approaches may be most effective for each tumor type.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24078694      PMCID: PMC3827919          DOI: 10.4049/jimmunol.1301966

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  38 in total

1.  Improved survival with ipilimumab in patients with metastatic melanoma.

Authors:  F Stephen Hodi; Steven J O'Day; David F McDermott; Robert W Weber; Jeffrey A Sosman; John B Haanen; Rene Gonzalez; Caroline Robert; Dirk Schadendorf; Jessica C Hassel; Wallace Akerley; Alfons J M van den Eertwegh; Jose Lutzky; Paul Lorigan; Julia M Vaubel; Gerald P Linette; David Hogg; Christian H Ottensmeier; Celeste Lebbé; Christian Peschel; Ian Quirt; Joseph I Clark; Jedd D Wolchok; Jeffrey S Weber; Jason Tian; Michael J Yellin; Geoffrey M Nichol; Axel Hoos; Walter J Urba
Journal:  N Engl J Med       Date:  2010-06-05       Impact factor: 91.245

2.  Altered expression of immune defense genes in pilocytic astrocytomas.

Authors:  Hervé Huang; Akira Hara; Taku Homma; Yasuhiro Yonekawa; Hiroko Ohgaki
Journal:  J Neuropathol Exp Neurol       Date:  2005-10       Impact factor: 3.685

3.  Sipuleucel-T immunotherapy for castration-resistant prostate cancer.

Authors:  Philip W Kantoff; Celestia S Higano; Neal D Shore; E Roy Berger; Eric J Small; David F Penson; Charles H Redfern; Anna C Ferrari; Robert Dreicer; Robert B Sims; Yi Xu; Mark W Frohlich; Paul F Schellhammer
Journal:  N Engl J Med       Date:  2010-07-29       Impact factor: 91.245

4.  Normal human monocytes exposed to glioma cells acquire myeloid-derived suppressor cell-like properties.

Authors:  Jennifer C Rodrigues; Guido C Gonzalez; Lei Zhang; George Ibrahim; John J Kelly; Michael P Gustafson; Yi Lin; Allan B Dietz; Peter A Forsyth; V Wee Yong; Ian F Parney
Journal:  Neuro Oncol       Date:  2009-12-22       Impact factor: 12.300

5.  Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma.

Authors:  Andrew T Parsa; James S Waldron; Amith Panner; Courtney A Crane; Ian F Parney; Jeffrey J Barry; Kristine E Cachola; Joseph C Murray; Tarik Tihan; Michael C Jensen; Paul S Mischel; David Stokoe; Russell O Pieper
Journal:  Nat Med       Date:  2006-12-10       Impact factor: 53.440

6.  High-dose chemotherapy and adoptive immunotherapy in the treatment of recurrent pediatric brain tumors.

Authors:  E Peres; G W Wood; J Poulik; R Baynes; S Sood; M H Abidi; J Klein; K Bhambhani; R Dansey; E Abella
Journal:  Neuropediatrics       Date:  2008-11-07       Impact factor: 1.947

7.  Adjuvant dendritic cell-based tumour vaccination for children with malignant brain tumours.

Authors:  Hilko Ardon; Steven De Vleeschouwer; Frank Van Calenbergh; Laurence Claes; Christof M Kramm; Stefan Rutkowski; Johannes E A Wolff; Stefaan W Van Gool
Journal:  Pediatr Blood Cancer       Date:  2010-04       Impact factor: 3.167

8.  Immune gene and cell enrichment is associated with a good prognosis in ependymoma.

Authors:  Andrew M Donson; Diane K Birks; Valerie N Barton; Qi Wei; Bette K Kleinschmidt-Demasters; Michael H Handler; Allen E Waziri; Michael Wang; Nicholas K Foreman
Journal:  J Immunol       Date:  2009-11-16       Impact factor: 5.422

9.  Possible involvement of the M2 anti-inflammatory macrophage phenotype in growth of human gliomas.

Authors:  Y Komohara; K Ohnishi; J Kuratsu; M Takeya
Journal:  J Pathol       Date:  2008-09       Impact factor: 7.996

10.  Intratumor T helper type 2 cell infiltrate correlates with cancer-associated fibroblast thymic stromal lymphopoietin production and reduced survival in pancreatic cancer.

Authors:  Lucia De Monte; Michele Reni; Elena Tassi; Daniela Clavenna; Ilenia Papa; Helios Recalde; Marco Braga; Valerio Di Carlo; Claudio Doglioni; Maria Pia Protti
Journal:  J Exp Med       Date:  2011-02-21       Impact factor: 14.307

View more
  96 in total

1.  ABC Transporter Inhibition Plus Dexamethasone Enhances the Efficacy of Convection Enhanced Delivery in H3.3K27M Mutant Diffuse Intrinsic Pontine Glioma.

Authors:  Vadim Tsvankin; Rintaro Hashizume; Hiroaki Katagi; James E Herndon; Christopher Lascola; Talaignair N Venkatraman; Daniel Picard; Brainard Burrus; Oren J Becher; Eric M Thompson
Journal:  Neurosurgery       Date:  2020-05-01       Impact factor: 4.654

2.  Glioma escape signature and clonal development under immune pressure.

Authors:  Cecile L Maire; Malte Mohme; Michael Bockmayr; Krystian D Fita; Kristoffer Riecken; Daniela Börnigen; Malik Alawi; Antonio Failla; Katharina Kolbe; Svenja Zapf; Mareike Holz; Katrin Neumann; Lasse Dührsen; Tobias Lange; Boris Fehse; Manfred Westphal; Katrin Lamszus
Journal:  J Clin Invest       Date:  2020-10-01       Impact factor: 14.808

Review 3.  Diffuse intrinsic pontine glioma: time for therapeutic optimism.

Authors:  Soumen Khatua; Wafik Zaky
Journal:  CNS Oncol       Date:  2014

4.  Screening genes crucial for pediatric pilocytic astrocytoma using weighted gene coexpression network analysis combined with methylation data analysis.

Authors:  H Zhao; W Cai; S Su; D Zhi; J Lu; S Liu
Journal:  Cancer Gene Ther       Date:  2014-09-26       Impact factor: 5.987

5.  Pre-treatment lymphopenia and indication of tumor-induced systemic immunosuppression in medulloblastoma.

Authors:  Seema Patel; Shiyang Wang; Matija Snuderl; Matthias A Karajannis
Journal:  J Neurooncol       Date:  2017-11-16       Impact factor: 4.130

6.  SOX2 immunity and tissue resident memory in children and young adults with glioma.

Authors:  Juan C Vasquez; Anita Huttner; Lin Zhang; Asher Marks; Amy Chan; Joachim M Baehring; Kristopher T Kahle; Kavita M Dhodapkar
Journal:  J Neurooncol       Date:  2017-06-15       Impact factor: 4.130

7.  Interleukin-6/STAT3 Pathway Signaling Drives an Inflammatory Phenotype in Group A Ependymoma.

Authors:  Andrea M Griesinger; Rebecca J Josephson; Andrew M Donson; Jean M Mulcahy Levy; Vladimir Amani; Diane K Birks; Lindsey M Hoffman; Steffanie L Furtek; Phillip Reigan; Michael H Handler; Rajeev Vibhakar; Nicholas K Foreman
Journal:  Cancer Immunol Res       Date:  2015-05-12       Impact factor: 11.151

8.  Specific expression of PD-L1 in RELA-fusion supratentorial ependymoma: Implications for PD-1-targeted therapy.

Authors:  Davis A Witt; Andrew M Donson; Vladimir Amani; Daniel C Moreira; Bridget Sanford; Lindsey M Hoffman; Michael H Handler; Jean M Mulcahy Levy; Kenneth L Jones; Anandani Nellan; Nicholas K Foreman; Andrea M Griesinger
Journal:  Pediatr Blood Cancer       Date:  2018-01-19       Impact factor: 3.167

Review 9.  Medulloblastoma development: tumor biology informs treatment decisions.

Authors:  Vidya Gopalakrishnan; Rong-Hua Tao; Tara Dobson; William Brugmann; Soumen Khatua
Journal:  CNS Oncol       Date:  2015

10.  BCOR Overexpression Is a Highly Sensitive Marker in Round Cell Sarcomas With BCOR Genetic Abnormalities.

Authors:  Yu-Chien Kao; Yun-Shao Sung; Lei Zhang; Achim A Jungbluth; Shih-Chiang Huang; Pedram Argani; Narasimhan P Agaram; Angelica Zin; Rita Alaggio; Cristina R Antonescu
Journal:  Am J Surg Pathol       Date:  2016-12       Impact factor: 6.394

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.